Evidence map›Paper›PMID 36116948›Full record

ArticleTransplantation proceedings2022

A Case Report of Breakthrough Infections With 2 SARS-CoV-2 Variants in a Lung Transplant Patient.

Luke D Mahan, Manish R Mohanka, John Joerns, Adrian Lawrence, Srinivas Bollineni, Vaidehi Kaza, Irina Timofte, Ricardo M La Hoz, Jeffrey Sorelle, Lance S Terada and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation proceedings, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luke D MahanDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Manish R MohankaDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
John JoernsDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Adrian LawrenceDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Srinivas BollineniDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Vaidehi KazaDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Irina TimofteDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Ricardo M La HozDivision of Infectious Disease and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Jeffrey SorelleDepartments of Genomics and Molecular Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
Lance S TeradaDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Corey D KershawDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Fernando TorresDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Amit BangaDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: banga@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A lung transplant (LT) patient developed 2 distinct episodes of COVID-19, confirmed by whole-genome sequencing, which was caused by the Delta, and then followed 6 weeks later, by the Omicron variant. The clinical course with Omicron was more severe, leading us to speculate that Omicron may not be any milder among LT patients. We discuss the potential mechanisms behind the Omicron not being any milder among LT patients and emphasize the need for outcomes data among these patients. Until such data become available, it may be prudent to maintain clinical equipoise as regards the relative virulence of the newer variants among LT patients.

Indexed as

COVID-19Lung TransplantationBreakthrough InfectionsHumansSARS-CoV-2

Identifiers

PMID36116948
PMCPMC9314265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.